Patent · US Active

Treatment for melanoma

US9572828B2 · kind B2 · utility

0Cited by
2References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 16, 2014
Grant dateFeb 21, 2017
Priority date
Expiry dateJul 6, 2034

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.